HP
BIIB icon

HealthInvest Partners’s Biogen BIIB Stock Holding History

HealthInvest Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,000
Closed -$3.26M – 11
2022
Q2 		$3.26M Sell
16,000
-12,000
-43% -$2.45M 7.52% 7
2022
Q1 		$5.9M Buy
+28,000
New +$6.09M 9.39% 4
2017
Q4 		$2.68M Sell
8,400
-12,000
-59% -$3.85M 5.65% 14
2017
Q3 		$6.39M Sell
20,400
-4,600
-18% -$1.36M 7.46% 9
2017
Q2 		$6.78M Buy
+25,000
New +$6.61M 8.46% 9

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HealthInvest Partners's BIIB Position: Q3 2022 in Review

HealthInvest Partners sold out of Biogen (BIIB) in Q3 2022, closing a stake of 16,000 shares — an estimated $3.26M sold.

HealthInvest Partners first reported a position in BIIB in Q2 2017 and held it in 5 quarters. The position peaked at $6.78M in Q2 2017. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.

  • HealthInvest Partners reported no remaining Biogen position as of Q3 2022 after selling out during the quarter.
  • HealthInvest Partners sold 16,000 Biogen shares in Q3 2022, an estimated $3.26M.
  • HealthInvest Partners first reported a position in Biogen in Q2 2017 and held it in 5 quarters.
  • HealthInvest Partners's Biogen position peaked at $6.78M in Q2 2017.
  • 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.

Based on HealthInvest Partners's 13F filing for Q3 2022, filed 21 Oct 2022.